MNKD
Mannkind Corp
Halal Rating :
Last Price
$6.01
Last updated:
Market Cap
-
7D Change
-2.04%
1 Year Change
74.06%
Company Overview
Industries
Exchange
Next Earnings Date
MannKind Corporation is a biopharmaceutical company focused on developing and commercializing therapeutic products for patients with endocrine and orphan lung diseases. Their main product is Afrezza, an FDA-approved inhaled insulin product for diabetes treatment. They also develop Tyvaso DPI, an inhalation powder used to treat pulmonary arterial hypertension.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $70.08m | $65.68m | - | $8.36m | 0.00% | 12.73% |
| June 30, 2024 | $72.39m | $75.7m | - | $19.93m | 0.00% | 26.32% |
| March 31, 2024 | $66.26m | $58.8m | - | $9.26m | 0.00% | 15.75% |
Company Impact
Help us evaluate Mannkind Corp's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.